Hangzhou Weiyuan Biotechnology

Hangzhou Weiyuan Biotechnology Co., Ltd. is a synthetic biology company founded in 2023. The company's technical foundation is built on the directed evolution of enzymes, multi-enzyme cascades, and the integration of enzymatic reactions with chemical synthesis. It leverages intelligent enzyme evolution and high-throughput strain screening as its core technology engine.

The founder and CEO, Wu Yan, graduated from Zhejiang University with a major in Bioengineering and has over two decades of experience in biopharmaceutical R&D and industrialization. The co-founder and CTO, Luo Zhibo, holds a PhD in Engineering from Tsinghua University and has a background in synthetic biology and chemical engineering research.

Weiyuan Biotechnology is focused on building a comprehensive enzyme library to produce chiral compounds, natural product extracts, and functional raw materials. The firm provides high-performance biological elements for the biomanufacturing industry, which are applied to the efficient production of chiral compounds, the enzymatic hydrolysis of active natural products, and the construction of cell-free multi-enzyme cascade systems. Its business serves other companies in the biotechnology sector. The company operates on a venture capital-backed, privately held ownership model and has completed Seed and Early Stage VC funding rounds.

Keywords: synthetic biology, enzyme evolution, biomanufacturing, chiral compounds, functional raw materials, directed evolution, multi-enzyme cascade, enzyme library, high-throughput screening, biopharmaceuticals, cell-free systems, natural product extraction, industrial enzymes, API, enzymatic hydrolysis